News Release

2019.12.16 Ethical Drugs
Notification of marketing of HARUROPI® TAPE in Japan (Transdermal, Parkinson’s disease treatment patch, development code: HP-3000)
2019.11.26 Research and Development
Notification of the results of Phase II clinical study of HP-5000 in the U.S. (Transdermal, pain relief and anti-inflammatory patch)
2019.11.12 lR Information
Notice regarding Cancellation of Treasury Shares
2019.10.28 Other
Notice regarding Support for The Disaster of Typhoon No. 19 in 2019
2019.10.15 Research and Development
Notification of FDA approval for SECUADO® in the U.S. (Transdermal, schizophrenia treatment patch, development code: HP-3070)
2019.10.10 lR Information
FY02/2020 Q2 Results Earnings Release Presentation
2019.10.01 lR Information
Notice regarding Results and Completion of Acquisition of Treasury Shares (Acquisition of treasury shares in accordance with the provisions of the Articles of Incorporation pursuant to Article 165, Paragraph 2 of the Companies Act)
2019.09.20 Research and Development
Notification of approval for manufacturing and marketing approval of HARUROPI® TAPE in Japan (Transdermal, Parkinson’s disease treatment patch, development code: HP-3000)
2019.09.06 Other
Notice regarding Support for The Disaster of The Torrential Rains in August 2019
2019.08.29 Research and Development
Notification of application for manufacturing and marketing approval of the additional indications of opioid analgesic naive cancer pain relief of FENTOS® TAPE (Transdermal, pain management patch,Development code: HFT-290) in Japan
2019.07.26 lR Information
Notice regarding Determination of Details of Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
2019.07.10 lR Information
FY02/2020 Q1 Results Earnings Release Presentation
2019.07.10 lR Information
Notice regarding Issuance of Stock Compensation-Type Share Options
2019.06.03 Ethical Drugs
Notification of Transfer of Marketing and Manufacturing Approval and Distribution Rights for the transdermal follicle and luteinizing hormone product “Menoaid® Combipatch”
2019.05.24 Research and Development
Notification of the results of the Phase II clinical study of HP-5070 in Japan (a transdermal drug for the treatment of primary local hyperhidrosis)
2019.05.24 Research and Development
Notification of the results of Phase III clinical study of HP-3150 in Japan for “cancer pain” (an analgesic transdermal drug containing NSAIDs)
2019.05.24 lR Information
Approach to and Policy on Reduction of Investment Unit, etc. 1.
2019.05.23 Management and Personnel
Executive Appointments
2019.05.17 Other
Salonpas® Named the World’s No. 1 OTC Topical Analgesic Patch Brand for the Third Consecutive Year
2019.04.26 Other
Notice regarding Name Change in Mail-Order Business
2019.04.10 lR Information
FY02/2019 Q4 Results Earnings Release Presentation
2019.04.10 Management and Personnel
Executive Appointments
2019.03.01 Subsidiaries and Affiliated Companies
Notification of a Subsidiary’s Share Transfer
2019.02.05
Hisamitsu Pharmaceutical and Kyowa Hakko Kirin sign Commercialization Agreement for HP-3000, a Potential New Transdermal Patch for Parkinson’s Disease in Japan
2019.01.11
FY02/2019 Q3 Results Earnings Release Presentation

PAGETOP